Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipatasertib plus abiraterone vs placebo plus abiraterone in metastatic castration-resistant prostate cancer
2016-004429-17Phase 3Completed
- Sponsor
- Roche
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Ipatasertib + abiraterone + prednisone/prednisolone with Placebo + abiraterone + prednisone/prednisolone (2 arms). Primary endpoint: Investigator-assessed radiographic progression-free survival (rPFS). Started Apr 2017; status: completed.
02
Drugs
ipatasertib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on 2016-004429-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004429-17.